STOCK TITAN

Dalrada Financial Corporation’s Wholly-Owned Subsidiary, Genefic, Inc. Announces New Telemedicine Services, Enters Booming Weight Loss Drug Market

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Dalrada Financial 's subsidiary, Genefic, Inc., introduces new telemedicine services to tap into the booming weight loss drug market. With a projected market value of nearly $100 billion by the end of the decade, Genefic aims to leverage its telemedicine service to offer clients direct access to its weight loss drug, capitalizing on the increasing popularity of such pharmaceuticals. The subsidiary's partnership with a renowned weight loss provider and the endorsement of celebrities like Oprah Winfrey and Elon Musk further solidify its market position.
La filiale di Dalrada Financial, Genefic, Inc., introduce nuovi servizi di telemedicina per penetrare il fiorente mercato dei farmaci per la perdita di peso. Con un valore di mercato proiettato di quasi 100 miliardi di dollari entro la fine del decennio, Genefic mira a sfruttare il suo servizio di telemedicina per offrire ai clienti accesso diretto al proprio farmaco dimagrante, sfruttando la crescente popolarità di tali farmaceutici. La partnership della filiale con un rinomato fornitore di servizi per la perdita di peso e l'avallo di celebrità come Oprah Winfrey ed Elon Musk rafforzano ulteriormente la sua posizione nel mercato.
La subsidiaria de Dalrada Financial, Genefic, Inc., introduce nuevos servicios de telemedicina para incursionar en el próspero mercado de medicamentos para la pérdida de peso. Con un valor de mercado proyectado de casi 100 mil millones de dólares para finales de la década, Genefic pretende aprovechar su servicio de telemedicina para ofrecer a los clientes acceso directo a su medicamento para perder peso, capitalizando la creciente popularidad de tales farmacéuticos. La asociación de la subsidiaria con un proveedor de pérdida de peso reconocido y el respaldo de celebridades como Oprah Winfrey y Elon Musk fortalecen aún más su posición en el mercado.
달라다 파이낸셜 자회사인 제네픽 인크가 급성장하는 체중 감량 약 시장에 진입하기 위해 새로운 원격 의료 서비스를 소개합니다. 이 자회사는 시장 가치가 10년 말까지 거의 1,000억 달러에 이를 것으로 예상하며, 이러한 의약품의 인기 증가를 활용하여 고객들에게 체중 감량 약에 직접 접근할 수 있는 원격 의료 서비스를 제공하고자 합니다. 또한 유명 체중 감량 제공업체와의 파트너십 및 오프라 윈프리와 일론 머스크와 같은 유명 인사의 지지로 그 시장 위치가 더욱 공고해졌습니다.
La filiale de Dalrada Financial, Genefic, Inc., lance de nouveaux services de télémédecine pour pénétrer le marché florissant des médicaments pour la perte de poids. Avec une valeur de marché projetée de près de 100 milliards de dollars d'ici la fin de la décennie, Genefic vise à utiliser son service de télémédecine pour offrir aux clients un accès direct à son médicament pour la perte de poids, tirant parti de la popularité croissante de tels produits pharmaceutiques. Le partenariat de la filiale avec un fournisseur reconnu pour la perte de poids et le soutien de célébrités telles qu'Oprah Winfrey et Elon Musk renforcent davantage sa position sur le marché.
Die Tochtergesellschaft von Dalrada Financial, Genefic, Inc., führt neue Telemedizindienste ein, um auf den boomenden Markt für Gewichtsverlustmedikamente zuzugreifen. Mit einem projizierten Marktwert von nahezu 100 Milliarden Dollar bis Ende des Jahrzehnts zielt Genefic darauf ab, seinen Telemedizindienst zu nutzen, um Kunden direkten Zugang zu seinem Gewichtsverlustmedikament zu bieten und somit auf die wachsende Beliebtheit solcher pharmazeutischer Produkte zu setzen. Die Partnerschaft der Tochtergesellschaft mit einem renommierten Anbieter für Gewichtsverlust sowie die Unterstützung durch Berühmtheiten wie Oprah Winfrey und Elon Musk verstärken ihre Marktposition zusätzlich.
Positive
  • None.
Negative
  • None.

The pharmaceutical subsidiary plans on capturing a large portion of a growing market with an innovative prescription method.

SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada,” “the Company”), announced today that its wholly-owned healthcare subsidiary, Genefic, Inc. (“Genefic”), has added a telemedicine service to its specialty pharmacy, allowing Genefic to efficiently offer clients direct access to its pharmaceuticals, including access to Genefic’s own weight loss drug, as the subsidiary enters the world’s booming weight loss drug market.

With the global weight loss drug market currently worth approximately $6 billion and projected to reach nearly $100 billion by the end of the decade, the overall popularity of weight loss drugs is driving a meteoric rise in market value.

Additionally, the expected compound annual growth rate (CAGR) of 45.7% suggests that 2024 is ideal for Genefic to enter the weight loss drug market, according to the subsidiary’s president, Dan Riley.

“Through the use of our robust new telemedicine service, we’re now able to offer a selection of the most successful weight loss drugs on the market today,” said Riley. He continued, “Genefic has already partnered with one of the world’s leading weight loss providers with more than two decades of established market acceptance. We know that this will accelerate further expansion of our client base.”

Increased awareness and acknowledgment of the efficacy of weight loss drugs have caused several celebrities including Oprah Winfrey, Elon Musk, Tracy Morgan, and Kelly Clarkson, among others, to tout their success—and the general public is following suit.

Brian Bonar, CEO of Dalrada, added, “We’re excited about providing access to these life-changing medications, and we believe this will open the door to similar opportunities within the specialty pharmacy space. Working within the weight loss drug market will present us with a wider reach than ever before while driving significant revenue.”

About Dalrada Corporation

Dalrada Financial Corporation (OTCQB: DFCO) is a multi-national holding company that develops, manufactures, and sells a robust suite of products and services in the Clean Energy and Health Care sectors. Dalrada’s core segments include Dalrada Climate Technology, which offers cutting-edge heat pump technology for industrial and residential applications, and Genefic Specialty Pharmacy, which provides end-to-end prescription services as well as patient advocacy and support.

Dalrada Financial Corporation consistently drives innovation that delivers maximum impact, bringing increased value to its shareholders.

For more information, please visit www.dalrada.com, and follow us on LinkedIn, Facebook, Twitter, and YouTube.

About Genefic

A wholly-owned subsidiary of Dalrada Financial Corporation, Genefic proudly delivers frontline health products and services through redesigned systems and reimagined patient care. Genefic’s unique pharmacy solution, Genefic Specialty Pharmacy, offers more than 30 years of dedicated expertise providing patient advocacy through end-to-end prescription services, medical education, and patient advocacy and support.

Forward-Looking Statements

Statements contained in this press release, other than statements of historical fact, particularly statements relating to cost reductions and the anticipated pre-tax savings from the cost reduction program, restructuring costs, footprint rationalization, simplifying and streamlining our operations, reducing complexity, enhancing the speed of decision-making, leveraging our sourcing capabilities and the timing of implementation and completion of the cost reduction program, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management based on information available to us at the time such statements are made. These statements, which are generally identifiable by the use of the words “will,” “believe,” “expect,” “intend,” “anticipate,” “estimate,” “forecast,” “project,” “plan,” and similar expressions, are subject to certain risks and uncertainties, are made as of the date hereof, and we undertake no duty or obligation to update them. Forward-looking statements are subject to the occurrence of many events outside the Company’s control and actual results and the timing of events may differ materially from those suggested or implied by such forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the US Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K.

Media contact: Isabella Monteparte (imonteparte@genefic.com)


FAQ

What did Dalrada Financial 's subsidiary, Genefic, Inc., announce?

Genefic, Inc. announced the introduction of new telemedicine services to its specialty pharmacy, enabling direct access to its weight loss drug and entry into the growing weight loss drug market.

What is the current value of the global weight loss drug market?

The global weight loss drug market is currently valued at approximately $6 billion.

What is the projected value of the weight loss drug market by the end of the decade?

The weight loss drug market is projected to reach nearly $100 billion by the end of the decade.

Who is the president of Genefic, Inc.?

The president of Genefic, Inc. is Dan Riley.

Which celebrities have endorsed weight loss drugs?

Celebrities like Oprah Winfrey, Elon Musk, Tracy Morgan, and Kelly Clarkson have endorsed weight loss drugs.

Who is the CEO of Dalrada Financial ?

The CEO of Dalrada Financial is Brian Bonar.

DALRADA FINCL CORP

OTC:DFCO

DFCO Rankings

DFCO Latest News

DFCO Stock Data

4.27M
89.29M
8%
Consulting Services
Industrials
Link
United States of America
Escondido